UNSPSC 51313107: Oxatomide

This classification denotes a histamine-1 receptor antagonist with the molecular formula C27H30N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J31IL9Z2EE, chemically known as 2h-benzimidazol-2-one, 1,3-dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)- but generally known as oxatomide, which bears US NIH Compound Identifier 4615. European Medicines Agency schedules Oxatomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09504MIG.

UNSPSC 51313107 Oxatomide is a Commodity code for a specific pharmaceutical product; however, the recent state and local opportunities posted under this code do not align with oxatomide procurement. Instead, the code shows activity in broader pharmaceutical and emergency-response drug procurement, including naloxone distribution systems, generic multi-source pharmaceuticals, and therapeutic pharmacy initiatives. State and local governments are using this code to procure emergency medications (naloxone), over-the-counter products, and to explore direct-to-manufacturer prescription fulfillment models that bypass traditional pharmacy benefit managers. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida; Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the recent buyers, with MMCAP operating a cooperative vehicle that extends purchasing authority to multiple states including Oregon.

Recent activity shows Seminole County issuing an IFB (IFB60459723LAS) on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, under a two-year contract with one-year renewal option. MMCAP issued an RFP (S1070000015802) in January 2026 due March 26, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities through three authorized wholesalers, with award effective July 1, 2026. The Texas HHS Commission posted an RFI (HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Geographic activity concentrates in Florida, Texas, and Minnesota, with cooperative purchasing reaching multiple states. The code shows material procurement velocity in emergency-response pharmaceuticals and multistate generic pharmaceutical contracting, though the nominal code name (oxatomide, a specific antihistamine) does not reflect the actual work being solicited.